Do bupropion, Valdoxan (agomelatine) and Ritalin (methylphenidate) cause dizziness and fatigue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Do Bupropion, Valdoxan (Agomelatine), and Ritalin (Methylphenidate) Cause Dizziness and Fatigue?

Yes, all three medications can cause dizziness, but their propensity to cause fatigue differs significantly: bupropion and methylphenidate typically reduce fatigue rather than cause it, while agomelatine (Valdoxan) can cause dizziness and other adverse effects but has poorly documented safety data.

Bupropion

Dizziness

Bupropion does cause dizziness as a commonly reported adverse event 1. According to FDA labeling, dizziness is listed among the adverse reactions, and when combined with dopaminergic drugs like levodopa or amantadine, CNS toxicity including vertigo and dizziness has been specifically reported 2.

Fatigue

Bupropion actually reduces fatigue rather than causing it. After repeated administration, bupropion significantly decreased asthenia-fatigue scores [44(3.2) vs. 53(4.1) for placebo; p = 0.034] 3. This anti-fatigue effect is similar to methylphenidate and represents a key distinguishing feature from other antidepressants.

Common pitfall: Clinicians may confuse initial insomnia (which bupropion does cause) with fatigue. The drug impairs sleep onset but paradoxically reduces daytime fatigue 3.

Valdoxan (Agomelatine)

Dizziness and Overall Tolerability

Agomelatine causes dizziness along with gastrointestinal and cutaneous disorders 4. However, the evidence quality is poor—agomelatine has unproven efficacy and poorly documented adverse effects 4.

Critical concern: The available evaluation lacks clinical trials comparing agomelatine to established antidepressants like tricyclics or SSRIs. Agomelatine was statistically more effective than placebo in only 3 of 7 trials, with questionable clinical relevance 4.

Fatigue

The evidence does not specifically address fatigue as an adverse effect of agomelatine, though the overall adverse effect profile remains inadequately characterized 4.

Ritalin (Methylphenidate)

Dizziness

Methylphenidate does cause dizziness with significant frequency. In a placebo-controlled trial of 206 children with ADHD, dizziness occurred with an odds ratio of 7.50 (95% CI = 1.93-29.13) compared to placebo 5. A systematic review confirmed that methylphenidate is associated with increased risk of dizziness 6.

Fatigue

Methylphenidate reduces fatigue rather than causing it. Similar to bupropion, methylphenidate decreased asthenia-fatigue scores [42(3.7) vs. 53(4.1) for placebo; p = 0.034] after sustained administration 3. This stimulant effect is the therapeutic mechanism in ADHD and narcolepsy treatment.

Important distinction: While methylphenidate can cause insomnia (which may lead to secondary fatigue if sleep is disrupted), the direct pharmacological effect is fatigue reduction, not induction 3.

Clinical Algorithm for Managing These Side Effects

For Dizziness:

  • Monitor closely during initial 1-2 weeks of therapy, as this is when adverse effects typically emerge 1
  • Consider dose reduction if dizziness is problematic, particularly with methylphenidate where lower doses may be better tolerated
  • Evaluate for drug interactions: Bupropion combined with dopaminergic drugs significantly increases dizziness risk 2
  • Rule out cardiovascular causes: All three medications can affect blood pressure and heart rate 3, 7

For Fatigue Concerns:

  • If fatigue worsens on bupropion or methylphenidate: Investigate alternative causes (depression worsening, sleep disruption, drug interactions) rather than attributing to the medication directly
  • If fatigue occurs with agomelatine: Consider switching to a better-studied antidepressant like an SSRI or tricyclic 4
  • Assess sleep quality: Both bupropion and methylphenidate impair sleep onset, which can cause secondary daytime fatigue despite their direct anti-fatigue effects 3

Monitoring Parameters:

  • Blood pressure and heart rate (all three medications can cause cardiovascular effects) 3, 7
  • Sleep quality and duration
  • Body weight (bupropion and methylphenidate both decrease weight) 3
  • Liver function tests for agomelatine (hepatotoxic risk) 4

Key caveat: The evidence for agomelatine is substantially weaker than for bupropion or methylphenidate. Given its unproven efficacy and poorly documented safety profile, it is better to use older, better-studied antidepressants 4.

References

Related Questions

In a patient taking sertraline 100 mg, bupropion 150 mg, and methylphenidate 36 mg who has anxiety, insomnia, and tremor, is stopping bupropion alone sufficient to resolve the excessive stimulation?
How should an adult patient already receiving sertraline and methylphenidate be managed, and when is it appropriate to add bupropion?
What is a safe starting dose of atomoxetine (Strattera) for a 14‑year‑old male with ADHD and depression, weighing 50 kg, who cannot tolerate stimulant medications?
In a 17-year-old female who discontinued atomoxetine (Strattera) due to anorexia and nausea and now presents with abdominal pain, shoulder/arm pain, and orthostatic dizziness despite increased food intake, what work‑up and management are recommended?
In a 15-year-old male with ADHD and a mood disorder who is currently taking escitalopram 10 mg daily and dexmethylphenidate extended-release 20 mg daily, and who has been off trazodone for two months after previously using 150 mg at bedtime, can trazodone be restarted at 50 mg?
What is the appropriate dose and dosing schedule of amoxicillin‑clavulanate suspension (250 mg/5 mL) for a 5‑year‑old child weighing 21 kg?
In a patient with heart failure, can vitamin B12 deficiency–induced megaloblastic anemia and colchicine toxicity each independently lower left ventricular ejection fraction, and can their combined effect further reduce it?
What dose of psyllium husk (in mg) is recommended for an 8‑week pregnant woman with constipation?
What is an appropriate empiric antibiotic regimen for an adult patient with intestinal obstruction and community-acquired pneumonia, assuming no known drug allergies?
What is the appropriate dosing regimen for phenazopyridine (Pyridium)?
Is it safe for an 8‑week pregnant woman to use Colace (docusate sodium), and what is the appropriate dosage?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.